Robert Barrow

CEO Robert Barrow sold 29,208 shares of DFTX at $45.03 under 10b5-1 plan; remains 1.10M shares post-sale

Robert Barrow, Chief Executive Officer, sold 29,208 shares on 2026-06-25 at $45.03 under a pre-arranged 10b5-1 trading plan adopted on 2022-06-15, reducing his holdings from 1.13M to 1.10M shares. The sale is scheduled, not discretionary. Definium Therapeutics is currently unprofitable with net income of $-77,098,000.00 over its most recent full fiscal year, with a $4.9B market cap. The stock is trading at $44.95, down 4.4% from its 52-week high of $47.01, though it has gained 91.1% over the past 30 days and 151.4% over 90 days. The pre-arranged nature of this transaction removes timing as an interpretable signal.

MindMed CEO Barrow purchased 1,000 shares in 2 transactions for $6,215.00 total amid -47.5% drawdown from 52-week high

Robert Barrow, Chief Executive Officer of MindMed, executed two separate share purchases totaling 1,000 shares for $6,215.00 on August 19–20, 2024. These purchases occurred at a blended average price of $6.22, while the current stock price of $6.17 is 47.5% below the 52-week high of $11.75 and has declined 22.2% over the prior 30 days and 26.6% over 90 days. The company reported a full-year net loss of $5.9M. While insider purchasing during a significant drawdown warrants attention, the position size—adding just 1,000 shares to an existing 564.5K share position—represents a modest 0.2% increment to his holdings, and the timing during broad-based weakness in the stock offers limited clarity on forward conviction absent additional context.